ClinicalTrials.gg
CompletedNCT04511728Updated May 31, 2022

A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia

A Phase 3 interventional study of HSK3486 and Propofol in Induction and Maintenance of General Anesthesia, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a multi-center, randomized, single-blind, propofol injectable emulsion parallel-controlled Phase III clinical study. A total of patients undergoing elective surgery are intended to be enrolled and randomly assigned to HSK3486 group and propofol group in a 2:1 ratio.

02

Conditions studied

  • Induction and Maintenance of General Anesthesia
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In-patients undergoing non-emergency, non-cardiothoracic, and non-extracerebral elective surgeries with expected operation time ≥ 1 h and requiring tracheal intubation under general anesthesia (patients whose surgery type may affect the collection of BIS parameter should not be included);
  2. Male or female, age ≥ 18 and ≤ 65 years old;
  3. (ASA) class I-III;
  4. (BMI) ≥ 18 and ≤ 30 kg/m\^2;
  5. Vital signs in the screening period meeting the following criteria:

    1. Respiration rate ≥ 10 and ≤ 24 breaths/min;
    2. SpO2 while breathing ≥ 95%;
    3. Systolic blood pressure ≥ 90 mmHg and ≤ 160 mmHg;
    4. Diastolic blood pressure ≥ 60 mmHg and ≤ 100 mmHg;
    5. Heart rate ≥ 55 and ≤ 100 bpm. (Note: The heart rate is judged by the results of monitoring after signing the ICF, and the heart rate results of 12-lead ECG examination are not used as the basis for judgment.)
  6. Subjects must understand the procedures and methods of this study, and be willing to provide and to complete the trial in strict accordance with study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to general anesthesia or previous history of anesthesia accidents;
  2. Known to and ingredients found in propofol injection and HSK3486 injectable emulsion (soybean oil, glycerin, triglycerides, egg lecithin, sodium oleate, and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide, and sugammadex sodium; cross-reactivity to halogenated anesthetics, jaundice or unexplained fever from previous use of halogenated anesthetics; contraindications to propofol;
  3. The following disease history or evidence that increases the risk of sedation/anesthesia is collected before/during screening:

    1. History of cardiovascular diseases: uncontrolled hypertension or SBP > 160 mmHg and/or DBP > 100 mmHg after treatment with antihypertensive drugs, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction, tachycardia/bradycardia requiring medication, or third-degree atrioventricular block within 6 months before screening, or interval of ≥ 450 ms (corrected using Fridricia's formula) during the screening period;
    2. History of respiratory diseases: respiratory insufficiency, history of obstructive pulmonary disorders, history of bronchospasm requiring treatment within 3 months before screening, and acute respiratory infection with one of the symptoms such as obvious fever, wheezing or productive cough within 1 week before the baseline period;
    3. History of neurological and psychiatric disorders: craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysms, cerebrovascular accidents; or schizophrenia, mania, long-term use of psychotropic drugs, history of cognitive impairment, etc.;
    4. History of gastrointestinal tract diseases: gastrointestinal retention, active bleeding, gastroesophageal reflux or obstruction, etc. which may cause reflux and aspiration judged by the investigator;
    5. Diabetic patients with uncontrolled blood glucose (fasting blood glucose ≥ 11.1 mmol/L, and/or random blood glucose ≥ 13.6 mmol/L);
    6. Patient with a history of uncontrolled and liver, kidney, blood system, nervous system or metabolic system diseases judged by the investigator to be unsuitable for this trial;
    7. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking > 2 units of alcohol (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol or 150 mL of wine);
    8. History of drug abuse within 3 months prior to screening;
    9. Serious infection, trauma, or major surgery within 4 weeks prior to screening.
  4. Any of the following respiratory management risks before/during screening:

    1. Asthma history and stridor;
    2. Sleep apnea syndrome;
    3. History or family history of malignant hyperthermia;
    4. History of intubation failure;
    5. Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati score III or IV).
  5. In receipt of any of the following drugs or therapies prior to screening:

    1. Participated in other clinical drug trials within 1 month prior to screening;
    2. Used drugs that may affect QT intervals within 2 weeks prior to screening;
    3. In receipt of propofol, other general sedatives/anesthetics, and/or opioid analgesics or compounds containing opioid analgesics within 3 days prior to screening.
  6. Patient whose laboratory test results measured at screening reach the following criteria and are verified through re-examination:

    1. ≤ 1.5 × 10\^9/L;
    2. count \< 80 × 10\^9/L;
    3. \< 90 g/L (no blood transfusion within the last 14 days);
    4. (ALT) and/or aspartate aminotransferase (AST) > 3.0 × ;
    5. Total > 2 × ULN;
    6. Blood creatinine > 1.5 × ULN.
  7. Women who are pregnant or breastfeeding; women of or men who are unwilling to use method during the trial; subjects who are planning pregnancy within 3 months after the completion of the trial (including male subjects);
  8. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    HSK3486

    Drug: HSK3486

  • Active comparator
    Propofol

    Drug: Propofol

Interventions

  • The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h

  • The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h

06

What researchers measure

Primary outcomes

  1. Success rate of anesthesia maintenance

    During the maintenance of anesthesia, the subject is not recovered and no remedial anesthetic is used

    Time frame: During maintenance of general anesthesia on day 1

Secondary outcomes

  1. Success rate of anesthesia induction

    During the induction of anesthesia, the subject achieves successful induction (i.e., MOAA/S ≤ 1) after administration of the study drug (up to 2 top-up doses), and no remedial anesthetic is used.

    Time frame: During induction of general anesthesia on day 1

  2. Percentage of time from the beginning of surgical skin incision to the end of surgery

    when bispectral index (BIS) is ≥ 40 and ≤ 60.

    Time frame: During maintenance of general anesthesia on day 1

  3. Time to recovery from anesthesia

    3 consecutive MOAA/S = 5. Record the time when MOAA/S = 5 is reached for the first time.

    Time frame: A period of time from discontinuation of the study drug to recovery after the end of surgery on day 1

  4. Time to respiratory recovery

    Respiratory rate ≥ 8 breaths/min and the tidal volume ≥ 5 mL/kg

    Time frame: A period of time from discontinuation of the study drug to respiratory recovery after the end of surgery on day 1

  5. Time from discontinuation of the study drug to 3 consecutive Aldrete score ≥ 9.

    Time frame: A period of time from discontinuation of the study drug to 3 consecutive Aldrete score ≥ 9 on day 1

  6. Number of patients with adverse events

    Safety endpoints

    Time frame: Pre-dose to 48 hours post-dose

Other outcomes

  1. Concentrations of HSK3486 and propofol in blood samples (sporadic sampling).

    Time frame: The end of the induction administration (to start of the maintenance administration) to 1~6 hours post-dose

07

Study locations

1 site
  • West China Hospital,Sichuan University
    Chengdu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 13, 2020
StartActual
Nov 24, 2020
Primary completionActual
Dec 31, 2020
CompletionActual
Jan 25, 2021
Last update
May 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04511728
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Nov 24, 2020
Primary completion
Dec 31, 2020
Completion
Jan 25, 2021
Last update
May 31, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion